Fortress Biotech, Inc. (FBIO) [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15
	10-K	10-K	10-K	10-K/A	10-K	10-K	10-K	10-K
Revenues:
Dermatology Product Sales	73.7	63.1	44.5	34.9	23.4	15.5	3.6	0.3
Pharmaceutical and Biotechnology Product Development	2.1	5.7	1.1	1.7	3.5	1.7	2.6	0.6
Financial Service Activities							10.3
Total revenues [+]	75.7	68.8	45.6	36.6	26.9	15.5	16.5	0.9
Products	71.0	63.1	44.5	34.9	23.4	15.5
Revenue growth [+]	10.1%	50.9%	24.5%	36.3%	73.2%	-5.8%	1809.6%
Dermatology Product Sales	16.7%	41.8%	27.5%	49.4%	50.6%	332.7%	1213.9%
Pharmaceutical and Biotechnology Product Development	-63.3%	429.7%	-37.5%	-51.3%	103.2%	-32.9%	335.6%
Cost of goods sold	35.1	34.6	16.0	11.7	6.8	4.2	0.8	-62.8
Gross profit	40.7	34.2	29.6	24.9	20.1	11.3	15.7	63.7
Gross margin	53.7%	49.8%	64.9%	68.0%	74.7%	73.0%	95.2%	7377.2%
Selling, general and administrative [+]	113.7	86.8	61.2	72.7	65.0	50.9	34.0	21.6
Sales and marketing				17.1	11.6		5.8	2.9
General and administrative [+]						50.9	28.2	18.7
General and administrative expenses				55.6	53.4	50.9	28.2	18.7
Other selling, general and administrative				55.6	53.4
Research and development	134.2	113.2	61.3	6.1	87.4	48.3	35.1	29.8
Other operating expenses	-3.6	22.7	1.4	56.9	-16.8	-1.8	6.7	51.4
EBITDA [+]	-200.5	-185.9	-92.0	-108.9	-114.1	-85.4	-59.2	-39.1
EBITDA growth	7.8%	102.1%	-15.5%	-4.6%	33.7%	44.3%	51.3%	93.3%
EBITDA margin	-264.7%	-270.3%	-201.7%	-297.3%	-424.5%	-550.0%	-359.0%	-4530.4%
Depreciation	3.1	2.6	2.3	0.7	1.4	0.7	0.9	0.0
EBITA	-203.6	-188.5	-94.3	-109.6	-115.5	-86.1	-60.1	-39.1
EBITA margin	-268.8%	-274.1%	-206.7%	-299.3%	-429.7%	-554.7%	-364.7%	-4533.4%
Amortization of intangibles				1.2
EBIT [+]	-203.6	-188.5	-94.3	-110.8	-115.5	-86.1	-60.1	-39.1
EBIT growth	8.0%	100.0%	-14.9%	-4.1%	34.2%	43.2%	53.6%	93.2%
EBIT margin	-268.8%	-274.1%	-206.7%	-302.5%	-429.7%	-554.7%	-364.7%	-4533.4%
Non-recurring items [+]					4.5	3.7	5.6	11.4
In-process research & development					4.1	4.2	5.5	11.4
Interest expense, net [+]	-1.4	-0.6	-1.5	-2.6	-1.1	-0.8	-0.3	-0.2
Interest expense	12.5	15.3	15.3	11.8			3.7	1.5
Interest income	1.4	0.6	1.5	2.6	1.1	0.8	0.3	0.2
Other income (expense), net [+]	1.2	38.8	5.2	18.4	-11.9	-8.5	-2.2	-2.1
Change in fair value of warrants	1.1	-0.4	-1.2	0.0	-0.7	-0.4	-1.0	-0.4
Other non-operating gains/losses					0.1	-0.3
Other					0.1	-0.3
Pre-tax income	-213.5	-164.4	-102.8	-101.7	-130.8	-97.5	-71.3	-53.9
Income taxes	0.4	0.5	0.1	0.0	0.0	1.5	0.0	0.0
Tax rate				0.0%	0.0%		0.0%	0.0%
Minority interest	-127.3	-100.1	-56.5	-61.7	-57.8	-33.0	-16.2	-5.5
Earnings from continuing ops	-86.6	-64.7	-46.5	-40.0	-59.5	-64.6	-55.1	-48.4
Earnings from discontinued ops					-24.6	-2.3
Net income	-86.6	-64.7	-46.5	-40.0	-84.1	-66.9	-55.1	-48.4
Net margin	-114.3%	-94.1%	-102.0%	-109.1%	-313.0%	-430.9%	-334.3%	-5611.6%

Basic EPS [+]	($0.97)	($0.79)	($0.65)	($0.73)	($1.37)	($1.55)	($1.38)	($1.24)
Growth	23.0%	22.6%	-11.5%	-46.7%	-11.6%	12.4%	11.4%	120.4%
Diluted EPS [+]	($0.97)	($0.79)	($0.65)	($0.73)	($1.37)	($1.55)	($1.38)	($1.24)
Growth	23.0%	22.6%	-11.5%	-46.7%	-11.6%	12.4%	11.4%	120.4%

Shares outstanding (basic) [+]	88.9	81.7	72.0	54.7	43.5	41.7	40.0	39.1
Growth	8.8%	13.5%	31.6%	25.9%	4.3%	4.2%	2.1%	7.8%
Shares outstanding (diluted) [+]	88.9	81.7	72.0	54.7	43.5	41.7	40.0	39.1
Growth	8.8%	13.5%	31.6%	25.9%	4.3%	4.2%	2.1%	7.8%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.